David Sheridan - Concepedia

Author

David Sheridan

Also Known As

D A Sheridan, D SHERIDAN, D Sheridan, D. A. SHERIDAN, D. A. Sheridan, D. SHERIDAN, D. Sheridan, D.A. Sheridan, David A Sheridan, David A. Sheridan

Publications

8.8K

Citations

H-Index

Concepts

All Affiliations

Newcastle University University of Plymouth University of Nottingham Newcastle upon Tyne Hospitals NHS Foundation Trust University of Turin

About

David Sheridan is an author at Newcastle University specializing in medicine, hepatology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	4.9K
2	Health Sciences	5	5	1.9K
3	Nursing	1	1	39
4	Diabetes	1	1	52
5	Epidemiology	1	1	38

David Sheridan

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Peter Eddowes, M. Sasso, Michael Allison, Gastroenterology HepatologyLiver Stiffness MeasurementNonalcoholic Fatty Liver DiseaseLiver PhysiologyAssessing Steatosis	2019	1.3K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study Philip N. Newsome, M. Sasso, Jonathan J Deeks, The Lancet. Gastroenterology & hepatology	2020	729
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study David Jones, Pol Boudes, Mark G. Swain, The Lancet. Gastroenterology & hepatology Molecular PharmacologySelective Ppar-δ AgonistHepatologyBiliary TractMedicine	2017	181
IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study Vijayaprakash Suppiah, Silvana Gaudieri, Nicola J. Armstrong, PLoS Medicine	2011	180
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease Mohammed Eslam, Ahmed M. Hashem, Reynold Leung, Nature Communications	2015	172
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C Khaled Thabet, Anastasia Asimakopoulos, Maryam Shojaei, Nature Communications	2016	127
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes Mohammed Eslam, Alessandra Mangia, Thomas Berg, Hepatology	2016	113
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis Mohammed Eslam, Duncan McLeod, Kebitsaone Simon Kelaeng, Nature Genetics InflammationFibrosisAutoimmune DiseaseDisease MechanismLiver Physiology	2017	96

Page 1